UNIBLASTIN 10MG ING

About

UNIBLASTIN 10MG INJ VIAL contains Vinblastine, a potent vinca alkaloid antineoplastic agent widely used in the treatment of various cancers. Its primary mechanism of action involves binding to tubulin, a crucial protein subunit of microtubules. This binding inhibits the polymerization of tubulin into microtubules, which are essential components of the mitotic spindle. Consequently, vinblastine disrupts the formation of the mitotic spindle, leading to the arrest of cells in the metaphase stage of cell division. This mitotic arrest ultimately triggers programmed cell death, or apoptosis, predominantly in rapidly dividing cancer cells. Administered intravenously, vinblastine is a key component of multi-drug chemotherapy regimens for conditions such as Hodgkin's lymphoma, non-Hodgkin's lymphoma, testicular cancer, and Kaposi's sarcoma, contributing significantly to disease control and remission induction.

Uses

• Treatment of Hodgkin's lymphoma.
• Management of non-Hodgkin's lymphoma.
• Therapy for testicular cancer.
• Treatment of Kaposi's sarcoma.

Directions For Use

Administered intravenously by a qualified healthcare professional. Strict adherence to dosage and administration guidelines is crucial.

Benefits

• Effective against various hematological malignancies.
• Can induce remission in certain cancers.
• Often used in combination chemotherapy.
• Well-established in oncology protocols.
• Contributes to disease control.
• Available in an injectable form for systemic delivery.

Side Effects

• Myelosuppression (leukopenia, thrombocytopenia)
• Nausea and vomiting
• Constipation
• Peripheral neuropathy
• Alopecia (hair loss)
• Jaw pain
• Muscle pain
• Fatigue
• Hypertension
• Stomatitis
• Extravasation at injection site
• SIADH (Syndrome of Inappropriate Antidiuretic Hormone)

Safety Measures

• Alcohol - Avoid alcohol during treatment as it may exacerbate gastrointestinal side effects or liver toxicity.
• Pregnancy - Contraindicated in pregnancy due to significant risk of fetal harm. Effective contraception is essential.
• Breastfeeding - Not recommended during breastfeeding as the drug is likely excreted in breast milk and can harm the infant.
• Liver - Use with extreme caution in patients with hepatic impairment; dose reduction is often necessary due to impaired metabolism.
• Kidney - Use with caution in patients with renal impairment; monitor closely for toxicity, though renal excretion is minor.
• Lung - Monitor for pulmonary toxicity, including bronchospasm, especially in patients with pre-existing lung conditions.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.